{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:39:47Z","timestamp":1781285987431,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alterations in the expression of the Duchenne muscular dystrophy (DMD) gene have been associated with the development, progression and survival outcomes of numerous cancers including tumours of the central nervous system. We undertook a detailed bioinformatic analysis of low-grade glioma (LGG) bulk RNAseq data to characterise the association between <jats:italic>DMD<\/jats:italic> expression and LGG survival outcomes. High <jats:italic>DMD<\/jats:italic> expression was significantly associated with poor survival in LGG with a difference in median overall survival between high and low <jats:italic>DMD<\/jats:italic> groups of over 7\u00a0years (P\u2009=\u2009&lt;\u20090.0001). In a multivariate model, <jats:italic>DMD<\/jats:italic> expression remained significant (P\u2009=\u20090.02) and was an independent prognostic marker for LGG. The effect of <jats:italic>DMD<\/jats:italic> expression on overall survival was only apparent in isocitrate dehydrogenase (IDH) mutant cases where non-1p\/19q co-deleted LGG patients could be further stratified into high\/low <jats:italic>DMD<\/jats:italic> groups. Patients in the high <jats:italic>DMD<\/jats:italic> group had a median overall survival time almost halve that of the low <jats:italic>DMD<\/jats:italic> group. The expression of the individual <jats:italic>DMD<\/jats:italic> gene products Dp71, Dp71ab and Dp427m were also significantly associated with overall survival in LGG which have differential biological effects relevant to the pathogenesis of LGG. Differential gene expression and pathway analysis identifies dysregulated biological processes relating to ribosome biogenesis, synaptic signalling, neurodevelopment, morphogenesis and immune pathways. Genes spanning almost the entirety of chromosome 1p are upregulated in patients with high overall <jats:italic>DMD<\/jats:italic>, Dp71 and Dp427m expression which worsens survival outcomes for these patients. We confirmed dystrophin protein is variably expressed in LGG tumour tissue by immunohistochemistry and, overall, demonstrate that <jats:italic>DMD<\/jats:italic> expression has potential utility as an independent prognostic marker which can further stratify IDH mutant LGG to identify those at risk of poor survival. This knowledge may improve risk stratification and management of LGG.<\/jats:p>","DOI":"10.1038\/s41598-022-07223-2","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:10:45Z","timestamp":1645787445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma"],"prefix":"10.1038","volume":"12","author":[{"given":"Michael","family":"Naidoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Hamarneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee R.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"7223_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000112061","volume":"119","author":"S McAvoy","year":"2007","unstructured":"McAvoy, S., Ganapathiraju, S., Perez, D. S., James, C. D. & Smith, D. I. DMD and IL1RAPL1: Two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors. Cytogenet. Genome Res. 119, 196\u2013203 (2007).","journal-title":"Cytogenet. Genome Res."},{"key":"7223_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000108309","volume":"118","author":"S McAvoy","year":"2007","unstructured":"McAvoy, S. et al. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet. Genome Res. 118, 260\u2013269 (2007).","journal-title":"Cytogenet. Genome Res."},{"key":"7223_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731\u2013740 (2003).","journal-title":"Lancet Neurol."},{"key":"7223_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1007\/s12035-019-01845-w","volume":"57","author":"M Naidoo","year":"2020","unstructured":"Naidoo, M. & Anthony, K. Dystrophin Dp71 and the neuropathophysiology of Duchenne muscular dystrophy. Mol. Neurobiol. 57, 1748\u20131767 (2020).","journal-title":"Mol. Neurobiol."},{"key":"7223_CR5","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0960-8966(18)30328-6","volume":"28","author":"A Ash","year":"2018","unstructured":"Ash, A., Machado, L., Raleigh, S. M. & Anthony, K. Neuropathophysiology of Duchenne muscular dystrophy: Involvement of the dystrophin isoform Dp71 in cell migration and proliferation. Neuromuscul. Disord. 28, S13\u2013S14 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"7223_CR6","first-page":"19","volume":"1","author":"L Jones","year":"2020","unstructured":"Jones, L., Naidoo, M., Machado, L. R. & Anthony, K. The Duchenne muscular dystrophy gene and cancer. Cell. Oncol. 1, 19\u201332 (2020).","journal-title":"Cell. Oncol."},{"key":"7223_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat. Genet. 46, 601\u2013606 (2014).","journal-title":"Nat. Genet."},{"key":"7223_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.18632\/oncotarget.10426","volume":"8","author":"LN Luce","year":"2017","unstructured":"Luce, L. N., Abbate, M., Cotignola, J. & Giliberto, F. Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations. Oncotarget 8, 145\u2013155 (2017).","journal-title":"Oncotarget"},{"key":"7223_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/cancers11070922","volume":"11","author":"O Mauduit","year":"2019","unstructured":"Mauduit, O. et al. Recurrent DMD deletions highlight specific role of Dp71 isoform in soft-tissue sarcomas. Cancers (Basel) 11, 922 (2019).","journal-title":"Cancers (Basel)"},{"key":"7223_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/07357907.2015.1084002","volume":"34","author":"S Tan","year":"2016","unstructured":"Tan, S. et al. Knocking down Dp71 expression in A549 cells reduces its malignancy in vivo and in vitro. Cancer Investig. 34, 16\u201325 (2016).","journal-title":"Cancer Investig."},{"key":"7223_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"7223_CR12","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 17, iv1\u2013iv62 (2015).","journal-title":"Neuro Oncol."},{"key":"7223_CR13","first-page":"680","volume":"31","author":"K Dixit","year":"2017","unstructured":"Dixit, K. & Raizer, J. Newer strategies for the management of low-grade gliomas. Oncology (Williston Park) 31, 680\u2013685 (2017).","journal-title":"Oncology (Williston Park)"},{"key":"7223_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11910-020-01040-8","volume":"20","author":"G Youssef","year":"2020","unstructured":"Youssef, G. & Miller, J. J. Lower grade gliomas. Curr. Neurol. Neurosci. Rep. 20, 21 (2020).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"7223_CR15","doi-asserted-by":"publisher","first-page":"iv4","DOI":"10.1093\/neuonc\/noz167.014","volume":"21","author":"M Solomons","year":"2019","unstructured":"Solomons, M. et al. Survival and seizure control have improved for adult low-grade gliomas over the last eleven years. Neuro Oncol. 21, iv4 (2019).","journal-title":"Neuro Oncol."},{"key":"7223_CR16","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","volume":"28","author":"AS Jakola","year":"2017","unstructured":"Jakola, A. S. et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann. Oncol. 28, 1942\u20131948 (2017).","journal-title":"Ann. Oncol."},{"key":"7223_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-019-03250-8","volume":"144","author":"Y Fukuya","year":"2019","unstructured":"Fukuya, Y. et al. Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas. J. Neurooncol. 144, 519\u2013528 (2019).","journal-title":"J. Neurooncol."},{"key":"7223_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","volume":"129","author":"A Olar","year":"2015","unstructured":"Olar, A. et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II\u2013III diffuse gliomas. Acta Neuropathol. 129, 585\u2013596 (2015).","journal-title":"Acta Neuropathol."},{"key":"7223_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"7223_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/not145","volume":"16","author":"J Zhao","year":"2014","unstructured":"Zhao, J., Ma, W. & Zhao, H. Loss of heterozygosity 1p\/19q and survival in glioma: A meta-analysis. Neuro Oncol. 16, 103 (2014).","journal-title":"Neuro Oncol."},{"key":"7223_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1093\/bioinformatics\/btr404","volume":"27","author":"F Ferrari","year":"2011","unstructured":"Ferrari, F., Solari, A., Battaglia, C. & Bicciato, S. PREDA: An R-package to identify regional variations in genomic data. Bioinformatics 27, 2446\u20132447 (2011).","journal-title":"Bioinformatics"},{"key":"7223_CR22","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/ijms20215429","volume":"20","author":"S Ruggieri","year":"2019","unstructured":"Ruggieri, S. et al. Dp71 expression in human glioblastoma. Int. J. Mol. Sci. 20, 5429 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"7223_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.hemonc.2018.11.001","volume":"12","author":"A Alkhaibary","year":"2019","unstructured":"Alkhaibary, A., Alassiri, A. H., AlSufiani, F. & Alharbi, M. A. Ki-67 labeling index in glioblastoma; Does it really matter?. Hematol. Oncol. Stem Cell Ther. 12, 82\u201388 (2019).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"7223_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00401-019-02069-x","volume":"138","author":"BW Day","year":"2019","unstructured":"Day, B. W. et al. The dystroglycan receptor maintains glioma stem cells in the vascular niche. Acta Neuropathol. 138, 1033 (2019).","journal-title":"Acta Neuropathol."},{"key":"7223_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4161\/cbt.5.4.2546","volume":"5","author":"A Calogero","year":"2006","unstructured":"Calogero, A. et al. Altered expression of \u03b1-dystroglycan subunit in human gliomas. Cancer Biol. Ther. 5, 441\u2013448 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"7223_CR26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/stem.1605","volume":"32","author":"E Bourkoula","year":"2014","unstructured":"Bourkoula, E. et al. Glioma-associated stem cells: A novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas. Stem Cells 32, 1239\u20131253 (2014).","journal-title":"Stem Cells"},{"key":"7223_CR27","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41593-019-0540-y","volume":"22","author":"E Jung","year":"2019","unstructured":"Jung, E. et al. Emerging intersections between neuroscience and glioma biology. Nat. Neurosci. 22, 1951\u20131960 (2019).","journal-title":"Nat. Neurosci."},{"key":"7223_CR28","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.febslet.2014.04.014","volume":"588","author":"L Golomb","year":"2014","unstructured":"Golomb, L., Volarevic, S. & Oren, M. p53 and ribosome biogenesis stress: The essentials. FEBS Lett. 588, 2571\u20132579 (2014).","journal-title":"FEBS Lett."},{"key":"7223_CR29","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-Tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252\u20137259 (2004).","journal-title":"Clin. Cancer Res."},{"key":"7223_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge, S. X., Son, E. W. & Yao, R. iDEP: An integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform. 19, 1\u201324 (2018).","journal-title":"BMC Bioinform."},{"key":"7223_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07223-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:06:02Z","timestamp":1669331162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07223-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7223"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07223-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3200"}}